Abstract:
SYNOPSIS:Acitretin (etretin), a second generation monoaromatic retinoid for use in the treatment of severe psoriasis and other dermatoses, is the major active metabolite of etretinate and possesses a similar therapeutic index; i.e. a similar ratio of clinical efficacy to adverse effects. When used alone at a maintenance dosage of 30 to 50mg daily, acitretin is effective in the treatment of psoriasis, causing a reduction in the severity of scaling, erythema and induration. Efficacy appears to be further enhanced by combination with psoralen-ultraviolet A photochemotherapy (PUVA) or ultraviolet B irradiation (UVB). These combinations reduce the time to lesion clearance and reduce the total radiation dose, improving overall safety. Comparative studies have confirmed the equivalence of acitretin and etretinate with regard to efficacy and toxicity. Adverse reactions are dose-related and generally typical of hypervitaminosis A. Alopecia and mucocutaneous symptoms such as cheilitis and drying of the mucous membranes are particularly prevalent. Hypertriglyceridaemia and elevation of cholesterol levels also occur. Examination of the pharmacokinetic profile of acitretin reveals its main advantage over etretinate. Acitretin is less lipophilic than etretinate, and its lack of sequestration into 'deep' fatty storage sites is reflected in a comparatively short terminal elimination half-life of 50 to 60 hours, compared with 120 days for etretinate. Due to its teratogenic potential, acitretin is strictly contraindicated in women of childbearing potential unless effective contraceptive measures are employed. Etretinate has been identified in plasma samples of some patients treated with acitretin. Thus, acetretin has an established place in the treatment of keratinising disorders, although its use in women of child-bearing potential must be accompanied by effective contraceptive measures, with a further 2-year contraceptive period after therapy completion. PHARMACODYNAMIC PROPERTIES:Investigation of the pharmacodynamic properties of acitretin has been restricted to some extent by the lack of a suitable experimental model. While in vitro results using normal human skin fibroblasts have been conflicting, acitretin generally modulates cell proliferation in cultures from hyperproliferative conditions such as psoriasis or neoplasia, and inhibits epidermal cell growth and differentiation. Acitretin also inhibits chemically induced hyperplasia, and causes regression or inhibits further growth and development of a number of established or transplantable carcinoma cell lines. The mechanism of action of acitretin in hyperproliferative disorders has yet to be fully elucidated; however, there appear to be a number of cellular effects. Target receptor site candidates include the cellular retinoic acid binding protein (CRABP), the epidermal growth factor (EGF) receptor, and retinoic acid nuclear receptors (RARs). Acitretin binds competitively to CRABP, a protein present in high concentrations in psoriatic plaques, and induces a marked elevation of CRABP levels in normal epidermis. However, 13-cis-acitretin does not bind to CRABP and acitretin may act via activation of RARs following conversion to a substance which binds to these receptors. In addition, the EGF receptor may be involved since acitretin has been found to influence its normal modulation of cell growth in both normal fibroblasts and squamous carcinoma cell lines. Cyclic adenosine monophosphate (cAMP)-dependent protein kinases and ornithine decarboxylase are probable mediators of the clinical response. In addition, acitretin demonstrates immunomodulatory and anti-inflammatory effects. It is hypothesised that the mechanisms entail inhibition of polymorphonuclear leucocyte accumulation in the stratum corneum, inhibition of lymphocytic blastogenesis by mitogens and stimulation of T cell-mediated cytotoxicity. PHARMACOKINETIC STUDIES:Following oral administration of the drug to patients with psoriasis, peak plasma acitretin concentrations range from 98 to 526 µg/L and are reached approximately 1.9 hours after a single 40mg dose. Acitretin is widely distributed in the body and systemic bioavailability is approximately 60%. It is extensively bound to albumin and has a high affinity for CRABP. Less than 5% of acitretin is bound to lipoproteins and this is reflected in its comparative lack of sequestration into fatty 'deep' storage sites and its short terminal elimination half-life relative to etretinate. Multiple dose studies have indicated an elimination half-life of 50 to 60 hours, and neither acitretin nor its isomeric counterpart, 13-cis-acitretin, is detectable in plasma 3 to 4 weeks after cessation of long term therapy. Isomeric interconversion is prevalent following oral administration of acitretin: mean maximum plasma concentrations of the 13-cis-isomeric metabolite are lower and occur slightly later than with acitretin. Plasma trough concentrations of this metabolite following long term administration of acitretin are about 5 times higher than those of the parent drug and the terminal elimination half-life is about 15 times longer. Acitretin is excreted predominantly via the renal and hepatic routes, as glucuronides in bile or as products with shortened side chains in urine. In blood, 13-cis-acitretin and 3 other metabolites have been identified. Liquid chromatography/mass spectroscopy has identified etretinate in plasma samples of some patients treated with acitretin. The results obtained so far are of concern with regard to a potential teratogenic effect in female patients. Therefore, an increase in the post therapy contraception period to 2 years instead of the 2 months previously advocated is appropriate until clarification of these recent results have been obtained. THERAPEUTIC EFFICACY:Trials with an initial double-blind phase and a subsequent noncomparative phase of up to 6 months duration have demonstrated the efficacy of orally administered acitretin (generally 25 to 75 mg/day) in the treatment of severe psoriasis. Variants of psoriasis vulgaris are notably susceptible to treatment and acitretin also appears to be effective against severe forms of pustular and erythrodermic psoriasis. Preliminary studies in small patient populations and a number of individual case reports suggest that acitretin, 30 to 50 mg/day, is beneficial in a variety of other cutaneous disorders including Darier's disease, lupus erythematosus and severe recessive x-linked ichthyosis. The rarity of these conditions prevents adequate extensive trials. Double-blinding in placebo-controlled trials is difficult to maintain due to the ubiquitous and distinctive nature of acitretin-induced adverse effects. However, double-blinding strategies have been used effectively in studies in which a dose-finding phase preceded a longer term noncomparative phase. Subjective assessments have revealed good to excellent (⩾ 50%) clearance of severe psoriasis in > 75% of patients: the severity of scaling, erythema and epidermal induration, and the percentage of body surface involvement, are reduced. Comparative studies in patients with psoriasis indicate that acitretin is comparable with etretinate in terms of therapeutic efficacy and adverse effects. When acitretin is combined with psoralen-ultraviolet A photochemotherapy (PUVA), clinical efficacy is improved, as evidenced by a higher complete remission rate and a reduced time to clearance of psoriasis. Total irradiation requirement is also reduced. Similar results are also achieved when acitretin is combined with ultraviolet B irradiation. ADVERSE EFFECTS:Acitretin therapy has distinctive adverse effects generally typical of hypervitaminosis A. While the incidence of mucocutaneous clinical adverse effects is high, their severity does not usually necessitate withdrawal of therapy, and they are completely reversed on cessation of treatment. Adverse effects are usually dose-related, although alopecia is also dependent on the duration of therapy. Mucocutaneous reactions are most common - drying of mucous membranes of the eyes, nose and lips, and cheilitis occurs in nearly all patients. Other clinical symptoms include alopecia, desquamation of the skin, pruritus and 'sticky' skin. Changes in the lipid profile are often observed. Hypertriglyceridaemia occurs in 35% of patients treated with acitretin 50 mg/day, but increases in serum cholesterol are less frequently reported. Liver enzyme levels are also adversely affected, hepatitis has been reported and acitretin therapy may have an adverse effect on bone. As with etretinate, acitretin is a potent teratogen. DOSAGE AND ADMINISTRATION:Initial acitretin dosage has usually ranged from 10 to 75 mg/day orally. After a few weeks, the dose should be individually adjusted to obtain optimum therapeutic response with tolerable adverse effects. Maintenance doses in such trials have ranged from 30 to 50 mg/day. Some authorities advocate low-dose therapy initially followed by a progressive dosage increase. Because of its potent teratogenicity and the detection of etretinate in patients treated with acitretin, the drug is contraindicated in women of childbearing potential unless effective contraceptive measures are adopted. It is essential that pregnancy be avoided for a full 2 years after therapy finishes, instead of the 2 months previously advocated.
journal_name
Drugsjournal_title
Drugsauthors
Pilkington T,Brogden RNdoi
10.2165/00003495-199243040-00010subject
Has Abstractpub_date
1992-04-01 00:00:00pages
597-627issue
4eissn
0012-6667issn
1179-1950pii
10.2165/00003495-199243040-00010journal_volume
43pub_type
杂志文章相关文献
DRUGS文献大全abstract::Oral abiraterone acetate, in combination with prednisone/prednisolone, is used to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. Abiraterone acetate was developed to specifically inhibit cytochrome P450 (CYP)17A1, which is an e...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/11208080-000000000-00000
更新日期:2011-10-22 00:00:00
abstract::Aspirin is currently the most widely prescribed treatment in the prevention of cardiovascular complications. The indications for the use of aspirin during pregnancy are, however, the subject of much controversy. Since the first evidence of the obstetric efficacy of aspirin in 1985, numerous studies have tried to deter...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-017-0823-0
更新日期:2017-11-01 00:00:00
abstract::Nivolumab (Opdivo(®)) is a fully human monoclonal antibody against programmed death receptor-1, a negative regulatory checkpoint molecule with a role in immunosuppression. The drug is administered intravenously and is approved for the treatment of unresectable malignant melanoma in Japan. The potential for intravenous...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0234-4
更新日期:2014-07-01 00:00:00
abstract::Conventional formulations of metoprolol have become well established in cardiovascular medicine and are particularly useful in the management of hypertension and ischaemic heart disease. Recently developed controlled release metoprolol delivery systems (metoprolol CR/ZOK and metoprolol OROS) were designed to overcome ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199243030-00006
更新日期:1992-03-01 00:00:00
abstract::The optimal pharmacological therapy of community-acquired pneumonia (CAP) is one of the most ardently debated issues in medicine. Presently, most guidelines recommend either a fluoroquinolone alone or dual therapy with a third-generation cephalosporin plus a macrolide in patients hospitalised with CAP, but few provide...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200565140-00004
更新日期:2005-01-01 00:00:00
abstract::Utilising a modified fixed-dose, 4 x 3 factorial design, the antihypertensive effects of all combinations of 4 doses of pinacidil (0, 12.5, 25 and 37.5 mg bid) with 3 doses of hydrochlorothiazide (0, 12.5 and 25 mg bid) were studied in patients with supine diastolic blood pressure of 95 to 110mm Hg. The decreases in s...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198800367-00015
更新日期:1988-01-01 00:00:00
abstract::In hospitals, oral quinolone therapy has lower daily associated costs (acquisition and administration) than most intravenous regimens. In addition, oral switch therapy shortens the duration of hospital stay for most patients. However, randomised trials are required to measure the economic impact of the switch to oral ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199958002-00014
更新日期:1999-01-01 00:00:00
abstract::Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan and Korea and is being researched in several countries. Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor with a t½ of approximately 24 h and unique pharmacok...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01086-0
更新日期:2019-05-01 00:00:00
abstract::Orlistat is a nonsystemically acting gastric and pancreatic lipase inhibitor that limits the absorption of dietary fat. A retrospective pooled analysis of three 2-year, double-blind, randomised, placebo-controlled trials involving patients with obesity revealed that orlistat recipients were more likely to experience a...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200161140-00011
更新日期:2001-01-01 00:00:00
abstract::Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. In April 2020, sacituzumab govitecan received accelerated approval in the US...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01337-5
更新日期:2020-07-01 00:00:00
abstract::This review focuses on the biochemical and clinical aspects of methylation in neuropsychiatric disorders and the clinical potential of their treatment with ademetionine (S-adenosylmethionine; SAMe). SAMe is required in numerous transmethylation reactions involving nucleic acids, proteins, phospholipids, amines and oth...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199448020-00002
更新日期:1994-08-01 00:00:00
abstract::The incidence of multiresistance in Gram-positive cocci causing infections in critically ill patients admitted to the intensive care unit (ICU) has increased notably in recent years. Thus, therapeutic proposals have been modified according to the emergence of multiresistant cocci and adapted to epidemiological markers...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-200666060-00003
更新日期:2006-01-01 00:00:00
abstract::A study was made of the clinical features and therapeutic response of 144 patients from whose sputum Branhamella catarrhalis was isolated. Typically, features of bronchopulmonary infection with cough productive of moderate amounts of purulent sputum, fever and dyspnoea were present. Of 74 patients who were infected in...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198600313-00023
更新日期:1986-01-01 00:00:00
abstract::In ten large, well-controlled, randomised trials (n = 203 to 1089), valdecoxib, a selective inhibitor of cyclo-oxygenase-2, was significantly more effective than placebo in the treatment of osteoarthritis, rheumatoid arthritis and pain associated with primary dysmenorrhoea, and for postsurgical analgesia. Valdecoxib 1...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200262140-00005
更新日期:2002-01-01 00:00:00
abstract::ROS1 gene rearrangements exist in 1-2% of non-small cell lung cancers, typically occurring in younger, never or light smokers with adenocarcinoma. ROS1 gene fusions are potent oncogenic drivers, the presence of which results in the susceptibility of tumours to ROS1-targeted therapy. Crizotinib was the first tyrosine k...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01164-3
更新日期:2019-08-01 00:00:00
abstract::The fluoroquinolones have been shown to be active in vitro against many mycobacterial species, including most strains of Mycobacterium tuberculosis complex and M. fortuitum, and some strains of M. kansasii, M. avium-intracellulare (MAI) complex and M. leprae. Ciprofloxacin, ofloxacin and sparfloxacin are the best stud...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199958002-00004
更新日期:1999-01-01 00:00:00
abstract::Aripiprazole (Abilify®) is an atypical antipsychotic indicated for the treatment of mania associated with bipolar I disorder. It is unique in its class, as it is a partial agonist of dopamine D(2) and D(3), and serotonin 5-HT(1A) receptors and a modest antagonist of 5-HT(2A) receptors. This article reviews the pharmac...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11208320-000000000-00000
更新日期:2012-01-01 00:00:00
abstract::Zaleplon is a pyrazolopyrimidine hypnotic agent which is indicated for the short term (2 to 4 weeks) management of insomnia. Zaleplon 5 and 10 mg at bedtime (usual recommended doses) significantly reduced sleep latency compared with placebo in clinical trials in nonelderly and elderly patients with insomnia. In genera...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200060020-00014
更新日期:2000-08-01 00:00:00
abstract::Resistance to the metabolic actions of insulin is thought to play a determining role in the aetiology of a great variety of disorders, including essential hypertension, accelerated atherosclerosis and cardiomyopathies. ACE inhibitors are recognised as being highly effective therapy for hypertension and cardiac insuffi...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200262090-00002
更新日期:2002-01-01 00:00:00
abstract::Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-016-0634-8
更新日期:2016-09-01 00:00:00
abstract::Chlamydia trachomatis infections are exceedingly prevalent, and can be associated with significant sequelae. The major infections are urethritis, cervicitis, salpingitis, and ocular infection. Chlamydial genital infections present as syndromes, where C. trachomatis is one of the causes of the syndrome. Because specifi...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198427050-00005
更新日期:1984-05-01 00:00:00
abstract::Ciclesonide nasal spray delivers the corticosteroid ciclesonide as a hypotonic spray via a metered-dose manual pump. Systemic exposure to ciclesonide and its active metabolite desisobutyryl-ciclesonide is low after intranasal administration. High protein binding (approximately 99%) and rapid first-pass clearance furth...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200868060-00009
更新日期:2008-01-01 00:00:00
abstract::Clascoterone (Winlevi®) is an androgen receptor inhibitor being developed as a topical cream and solution by Cassiopea (a spin-out company of Cosmo Pharmaceuticals) for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. Although the exact mechanism of action of clasc...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01417-6
更新日期:2020-11-01 00:00:00
abstract::The incidence of pulmonary embolism (PE) and venous thromboembolism (VTE) is higher in pregnant patients than in non-pregnant patients. The incidence of thrombosis in all pregnancies is reported to be between 0.05 and 1%, and an incidence as high as 3% may be present in women after caesarean section. Anticoagulant med...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200262030-00004
更新日期:2002-01-01 00:00:00
abstract::Anidulafungin is an antifungal drug belonging to the echinocandin class with a potent in vitro fungicidal activity against a wide range of Candida species, including C. glabrata and C. krusei. Anidulafungin is also active in vitro against moulds belonging to the genus Aspergillus and some dematiaceous genera. Furtherm...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11315560-000000000-00000
更新日期:2009-01-01 00:00:00
abstract::Rabeprazole is an inhibitor of the gastric proton pump. It causes dose-dependent inhibition of acid secretion and has a more rapid onset of action than omeprazole. Duodenal ulcers healed faster after treatment with rabeprazole 20 or 40 mg/day than placebo or ranitidine 150 mg 4 times daily and at a generally similar r...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199958040-00014
更新日期:1999-10-01 00:00:00
abstract::Growth hormone deficiency (GHD) in the adult has now been fully recognised as a clinical entity characterised by abnormal body composition, osteopenia, impaired quality of life, cardiac dysfunction and an adverse lipid profile. While short-term studies of GH replacement have demonstrated irrefutably a favourable effec...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200262160-00006
更新日期:2002-01-01 00:00:00
abstract::Knowledge of the structure, function and distribution of the components of the renin-angiotensin-aldosterone system (RAS) and the integrated physiological role of this hormonal system is rapidly increasing, although many questions remain unanswered. The primary structure and localisation of RAS such as renin, prorenin...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199000391-00005
更新日期:1990-01-01 00:00:00
abstract::This paper reviews the evidence that, in patients with hypertension, end-organ damage correlates more closely with blood pressure values obtained by ambulatory blood pressure monitoring than with those obtained by conventional sphygmomanometry. However, ambulatory blood pressure monitoring is not suitable for routine ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199200441-00004
更新日期:1992-01-01 00:00:00
abstract::The incidence of squamous cell carcinoma of the head and neck (SCCHN) is on the rise in the US despite a drop in cigarette smoking rates. Much of this rise is due to the increasing incidence of SCCHN attributable to human papillomavirus (HPV). HPV-related SCCHN has a high cure rate, which contributes to the stable dea...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11592540-000000000-00000
更新日期:2011-08-20 00:00:00